Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$17.53 USD

17.53
5,608,806

+0.57 (3.36%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $17.55 +0.02 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Zacks Equity Research

BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.

Zacks Equity Research

Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Altimmune's (ALT) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the development of its lead pipeline candidate, pemvidutide.

Zacks Equity Research

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Bayer (BAYRY) Intends to Slash Dividends Amid Challenges

by Zacks Equity Research

Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.

Zacks Equity Research

Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?

by Zacks Equity Research

Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.

Zacks Equity Research

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

by Zacks Equity Research

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

Zacks Equity Research

Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow

by Zacks Equity Research

Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.

Zacks Equity Research

Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.